Table 1. Characteristics of Patients With Breast Cancer Stratified by Hormone Receptor Status, From the Surveillance, Epidemiology, and End Results Database, 1990-2015a.
| Characteristic | No./Total No. (%) | ||||
|---|---|---|---|---|---|
| All Patients (N = 823 399) | ER+/PR+ (n = 553 165) | ER+/PR− (n = 100 319) | ER−/PR+ (n = 13 368) | ER−/PR− (n = 156 547) | |
| Age at diagnosis, median (range), y | 60 (8-108) | 61 (17-107) | 62 (8-108) | 53 (19-104) | 56 (10-105) |
| Age group at diagnosis, y | |||||
| <30 | 4800 (0.6) | 2330 (0.4) | 524 (0.5) | 149 (1.1) | 1797 (1.1) |
| 30-39 | 43 781 (5.3) | 24 023 (4.3) | 4328 (4.3) | 1365 (10.2) | 14 065 (9.0) |
| 40-49 | 152 492 (18.5) | 102 812 (18.6) | 12 264 (12.2) | 3676 (27.5) | 33 740 (21.6) |
| 50-59 | 203 933 (24.8) | 131 427 (23.8) | 25 850 (25.8) | 3415 (25.5) | 43 241 (27.6) |
| 60-69 | 196 670 (23.9) | 135 831 (24.6) | 26 027 (25.9) | 2398 (17.9) | 32 414 (20.7) |
| 70-79 | 143 324 (17.4) | 101 802 (18.4) | 19 507 (19.4) | 1573 (11.8) | 20 442 (13.1) |
| ≥80 | 78 399 (9.5) | 54 940 (9.9) | 11 819 (11.8) | 792 (5.9) | 10 848 (6.9) |
| Sex, No. (%) | |||||
| Male | 5397 (0.7) | 4570 (0.8) | 542 (0.5) | 50 (0.4) | 235 (0.2) |
| Female | 818 002 (99.3) | 548 595 (99.2) | 99 777 (99.5) | 13 318 (99.6) | 156 312 (99.8) |
| Race | |||||
| White | 668 102/819 361 (81.5) | 459 856/550 273 (83.6) | 81 126/99 864 (81.2) | 10 200/13 308 (76.6) | 116 920/155 916 (75.0) |
| Black | 83 371/819 361 (10.2) | 44 235/550 273 (8.0) | 10 953/99 864 (11.0) | 1902/13 308 (14.3) | 26 281/155 916 (16.9) |
| Other | 67 888/819 361 (8.3) | 46 182/550 273 (8.4) | 7785/99 864 (7.8) | 1206/13 308 (9.1) | 12 715/155 916 (8.2) |
| Unknown, No. | 4038 | 2892 | 455 | 60 | 631 |
| Tumor size, cm | |||||
| <2 | 423 898/771 918 (54.9) | 313 287/524 472 (59.7) | 48 337/92 945 (52.0) | 5480/12 088 (45.3) | 56 794/142 413 (39.9) |
| 2-5 | 292 876/771 918 (37.9) | 180 867/524 472 (34.5) | 36 696/92 945 (39.5) | 5483/12 088 (45.4) | 69 830/142 413 (49.0) |
| >5 | 55 144/771 918 (7.1) | 30 318/524 472 (5.8) | 7912/92 945 (8.5) | 1125/12 088 (9.3) | 15 789/142 413 (11.1) |
| Unknown, No. | 51 481 | 28 693 | 7374 | 1280 | 14 134 |
| Lymph node status | |||||
| Positive | 270 137/780 835 (34.6) | 171 865/526 696 (32.6) | 34 187/94 353 (36.2) | 4909/12 428 (39.5) | 59 176/147 358 (40.2) |
| Negative | 510 698/780 835 (65.4) | 354 831/526 696 (67.4) | 60 166/94 353 (63.8) | 7519/12 428 (60.5) | 88 182/147 358 (59.8) |
| Unknown, No. | 42 564 | 26 469 | 5966 | 940 | 9189 |
| Distant metastasis | |||||
| M0 | 777 844/812 878 (95.7) | 526 944/546 840 (96.4) | 93 074/98 872 (94.1) | 12 464/13 183 (94.5) | 145 362/153 983 (94.4) |
| M1 | 35 034/812 878 (4.3) | 19 896/546 840 (3.6) | 5798/98 872 (5.9) | 719/13 183 (5.5) | 8621/153 983 (5.6) |
| Unknown, No. | 10 521 | 6325 | 1447 | 185 | 2564 |
| Adjusted AJCC sixth edition stage | |||||
| 0 | 589/788 671 (0.1) | 118/531 107 (0.0) | 110/95 678 (0.1) | 18/12 620 (0.1) | 343/149 266 (0.2) |
| I | 370 170/788 671 (46.9) | 272 254/531 107 (51.3) | 42 494/95 678 (44.4) | 4807/12 620 (38.1) | 50 615/149 266 (33.9) |
| II | 278 214/788 671 (35.3) | 178 453/531 107 (33.6) | 33 113/95 678 (34.6) | 4869/12 620 (38.6) | 61 779/149 266 (41.4) |
| III | 104 664/788 671 (13.3) | 60 386/531 107 (11.4) | 14 163/95 678 (14.8) | 2207/12 620 (17.5) | 27 908/149 266 (18.7) |
| IV | 35 034/788 671 (4.4) | 19 896/531 107 (3.7) | 5798/95 678 (6.1) | 719/12 620 (5.7) | 8621/149 266 (5.8) |
| Unknown, No. | 34 728 | 22 058 | 4641 | 748 | 7281 |
| Tumor grade | |||||
| I | 156 063/756 167 (20.6) | 135 287/509 817 (26.5) | 16 269/90 602 (18.0) | 864/11 866 (7.3) | 3643/143 882 (2.5) |
| II | 322 437/756 167 (42.6) | 253 316/509 817 (49.7) | 38 301/90 602 (42.3) | 3212/11 866 (27.1) | 27 608/143 882 (19.2) |
| III | 267 554/756 167 (35.4) | 117 022/509 817 (23.0) | 34 853/90 602 (38.5) | 7454/11 866 (62.8) | 108 225/143 882 (75.2) |
| IV | 10 113/756 167 (1.3) | 4192/509 817 (0.8) | 1179/90 602 (1.3) | 336/11 866 (2.8) | 4406/143 882 (3.1) |
| Unknown, No. | 67 232 | 43 348 | 9717 | 1502 | 12 665 |
| Histology type, No. (%)b | |||||
| IDC, code 8500/3 | 603 203 (73.3) | 394 003 (71.2) | 71 228 (71.0) | 10 409 (77.9) | 127 563 (81.5) |
| ILC, code 8520/3 | 68 336 (8.3) | 54 349 (9.8) | 10 913 (10.9) | 569 (4.3) | 2505 (1.6) |
| Mixed IDC and ILC, code 8522/3 | 54 061 (6.6) | 43 948 (7.9) | 6577 (6.6) | 516 (3.9) | 3020 (1.9) |
| Other types | 97 799 (11.9) | 60 865 (11.0) | 11 601 (11.6) | 1874 (14.0) | 23 459 (15.0) |
| ERBB2 status | |||||
| Positive | 43 845/277 691 (15.8) | 21 669/198 143 (10.9) | 7943/31 409 (25.3) | 911/2934 (31.0) | 13 322/45 205 (29.5) |
| Negative | 233 846/277 691 (84.2) | 176 474/198 143 (89.1) | 23 466/31 409 (74.7) | 2023/2934 (69.0) | 31 883/45 205 (70.5) |
| Unknown or borderline, No. | 545 708 | 355 022 | 68 910 | 10 434 | 111 342 |
| Surgery status | |||||
| Yes | 671 516/716 907 (93.7) | 459 120/486 214 (94.4) | 79 987/86 857 (92.1) | 8581/9315 (92.1) | 123 828/134 521 (92.1) |
| No | 45 391/716 907 (6.3) | 27 094/486 214 (5.6) | 6870/86 857 (7.9) | 734/9315 (7.9) | 10 693/134 521 (7.9) |
| Unknown, No. | 106 492 | 66 951 | 13 462 | 4053 | 22 026 |
| Chemotherapy status | |||||
| Yes | 339 415 (41.2) | 185 752 (33.6) | 42 416 (42.3) | 7754 (58.0) | 103 493 (66.1) |
| No or unknown | 483 984 (58.8) | 367 413 (66.4) | 57 903 (57.7) | 5614 (42.0) | 53 054 (33.9) |
| Radiation therapy status | |||||
| Yes | 411 436 (50.0) | 283 848 (51.3) | 48 389 (48.2) | 6134 (45.9) | 73 065 (46.7) |
| No or unknown | 411 963 (50.0) | 269 317 (48.7) | 51 930 (51.8) | 7234 (54.1) | 83 482 (53.3) |
| Vital status | |||||
| Alive | 591 558 (71.8) | 414 154 (74.9) | 66 398 (66.2) | 8472 (63.4) | 102 534 (65.5) |
| Died of breast cancer | 115 524 (14.0) | 58 485 (10.6) | 17 371 (17.3) | 3104 (23.2) | 36 564 (23.4) |
| Died of other cause | 116 317 (14.1) | 80 526 (14.6) | 16 550 (16.5) | 1792 (13.4) | 17 449 (11.1) |
Abbreviations: AJCC, American Joint Committee on Cancer; ER, estrogen receptor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; PR, progesterone receptor.
a
P < .001 for all comparisons, calculated using the Pearson χ2 test.
b
By International Classification of Diseases for Oncology, Third Edition histopathology code.